No Data
No Data
Express News | Exact Sciences Reported On Data Showing High Sensitivity And Specificity For The Non-Endoscopic Oncoguard Esophagus Test That Is Currently In Development For Esophageal Cancer and Pre-Cancer
Exact Sciences Advances Development of Non-Endoscopic Oncoguard Esophagus Test to Screen for Esophageal Cancer and Pre-Cancer
Results indicate potential of a minimally invasive screening tool to detect most common form of Esophageal Cancer, a highly treatable cancer if caught early Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of
Exact Sciences Named 2024 Gallup Exceptional Workplace Award Winner
Company also receives national and regional Top Workplace honors from USA Today and Wisconsin State Journal Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, today
Trending Stocks Today: Stoke Therapeutics Shoots up 80% Post-Market
March 25th - US stocks trending post-market.Gainers: $Stoke Therapeutics(STOK.US)$ surges 80% to $11.7 with a turnover of $21.25 million. $Reddit(RDDT.US)$ gets a 12.04% boost to $67 with a turnover o
Analysts Offer Insights on Healthcare Companies: Exact Sciences (EXAS) and Geron (GERN)
Exact Sciences' (EXAS) BLUE-C Study Results Published in NEJM
No Data